Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $84 | In Stock | |
5 mg | $198 | In Stock | |
10 mg | $313 | In Stock | |
25 mg | $622 | In Stock | |
50 mg | $872 | In Stock | |
1 mL x 10 mM (in DMSO) | $259 | In Stock |
Description | PARP1-IN-5 dihydrochloride is an orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer. |
In vitro | PARP1-IN-5 dihydrochloride (0.1~10 μM) can significantly increase the cytotoxicity of CBP on A549 cells in a dose-dependent manner. PARP1-IN-5 dihydrochloride (0.1~10 μM) decreases the expressions of MCM2-7 on SK-OV-3 cells. PARP1-IN-5 dihydrochloride (0.1~320 μM) has little cytotoxic effects on A549 cells. PARP1-IN-5 dihydrochloride can significantly decrease the PAR level on SK-OV-3 cells[1]. PARP1-IN-5 dihydrochloride exerts antitumor effects through PARP-1. PARP1-IN-5 dihydrochloride could increase the γ-H2AX expression[1]. |
In vivo | PARP1-IN-5 dihydrochloride (1000 mg/kg; p.o.) shows that there is no significant difference in the body weight and blood routine[1]. PARP1-IN-5 dihydrochloride (25 and 50 mg/kg; p.o.; 12 days) significantly enhances the inhibitory effect of carboplatin on A549 cells at 50 mg/kg[1]. PARP1-IN-5 dihydrochloride (50 mg/kg; p.o.) positively correlates with the expression of PARP-1[1]. PARP1-IN-5 dihydrochloride can decrease the expression of PAR and upregulate the expression of γ-H2AX [1]. |
Molecular Weight | 537.46 |
Formula | C25H26Cl2N2O5S |
Cas No. | 2823308-89-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 125 mg/mL (232.58 mM) H2O: 1 mg/mL (1.86 mM) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/H2O
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.